Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).

John M. Varlotto,Zhuoxin Sun,Suresh S. Ramalingam,Heather A. Wakelee,Christine M. Lovly,Kurt R. Oettel,Gregory A. Masters,Nate Pennell

Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).

2021

John M. Varlotto
Zhuoxin Sun
Suresh S. Ramalingam
Heather A. Wakelee
Christine M. Lovly
Kurt R. Oettel
Gregory A. Masters
Nate Pennell

TPS8584Background: Platinum-based concurrent chemoradiation(CRT) followed by one year of the human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody, durvalumab, which blocks the interaction of P...

Keywords:

Internal medicine
human immunoglobulin
Medicine
Oncology
concurrent chemoradiation
Stage (cooking)
Durvalumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations